Vermillion Stock Price, News & Analysis (NASDAQ:VRML)

$1.81 0.02 (1.12 %)
(As of 12/11/2017 09:54 AM ET)
Previous Close$1.79
Today's Range$1.70 - $1.85
52-Week Range$0.91 - $2.85
Volume28,800 shs
Average Volume91,708 shs
Market Capitalization$108.60 million
P/E RatioN/A
Dividend YieldN/A
Beta2.37

About Vermillion (NASDAQ:VRML)

Vermillion logoVermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.

Receive VRML News and Ratings via Email

Sign-up to receive the latest news and ratings for VRML and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Diagnostics & Testing
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VRML
CUSIPN/A
Phone512-519-0400

Debt

Debt-to-Equity Ratio0.26%
Current Ratio3.74%
Quick Ratio3.67%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.64 million
Price / Sales41.14
Cash FlowN/A
Price / CashN/A
Book Value$0.07 per share
Price / Book25.86

Profitability

Trailing EPS($0.20)
Net Income$-14,960,000.00
Net Margins-332.10%
Return on Equity-200.44%
Return on Assets-114.50%

Miscellaneous

Employees33
Outstanding Shares60,000,000

Vermillion (NASDAQ:VRML) Frequently Asked Questions

What is Vermillion's stock symbol?

Vermillion trades on the NASDAQ under the ticker symbol "VRML."

How were Vermillion's earnings last quarter?

Vermillion, Inc. (NASDAQ:VRML) announced its quarterly earnings data on Wednesday, November, 8th. The company reported ($0.06) EPS for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.02. The firm earned $0.70 million during the quarter. Vermillion had a negative return on equity of 200.44% and a negative net margin of 332.10%. View Vermillion's Earnings History.

Where is Vermillion's stock going? Where will Vermillion's stock price be in 2017?

1 brokerages have issued 12-month price objectives for Vermillion's stock. Their predictions range from $2.25 to $2.25. On average, they anticipate Vermillion's stock price to reach $2.25 in the next twelve months. View Analyst Ratings for Vermillion.

Who are some of Vermillion's key competitors?

Who are Vermillion's key executives?

Vermillion's management team includes the folowing people:

  • James T. LaFrance, Chairman of the Board (Age 58)
  • Valerie Barber Palmieri, President, Chief Executive Officer (Age 53)
  • Fred Ferrara, Chief Operating Officer (Age 49)
  • Donald G. Munroe Ph.D., Senior Vice President - Business Development, Chief Scientific Officer (Age 58)
  • Eric J. Schoen, Chief Accounting Officer, Vice President - Finance (Age 46)
  • James S. Burns, Independent Director (Age 69)
  • Veronica G. H. Jordan Ph.D., Independent Director (Age 64)
  • David R Schreiber, Independent Director (Age 55)
  • Carl Severinghaus, Independent Director (Age 63)
  • Eric K. Varma M.D., Independent Director (Age 33)

Who owns Vermillion stock?

Vermillion's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Birchview Capital LP (4.39%) and Essex Investment Management Co. LLC (0.39%). Company insiders that own Vermillion stock include Eric Schoen, Jack W Schuler, Larry N Feinberg, Valerie Barber Palmieri and Veronica Gh Jordan. View Institutional Ownership Trends for Vermillion.

Who bought Vermillion stock? Who is buying Vermillion stock?

Vermillion's stock was purchased by a variety of institutional investors in the last quarter, including Birchview Capital LP and Essex Investment Management Co. LLC. Company insiders that have bought Vermillion stock in the last two years include Eric Schoen, Jack W Schuler, Larry N Feinberg, Valerie Barber Palmieri and Veronica Gh Jordan. View Insider Buying and Selling for Vermillion.

How do I buy Vermillion stock?

Shares of Vermillion can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vermillion's stock price today?

One share of Vermillion stock can currently be purchased for approximately $1.81.

How big of a company is Vermillion?

Vermillion has a market capitalization of $108.60 million and generates $2.64 million in revenue each year. The company earns $-14,960,000.00 in net income (profit) each year or ($0.20) on an earnings per share basis. Vermillion employs 33 workers across the globe.

How can I contact Vermillion?

Vermillion's mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company can be reached via phone at 512-519-0400 or via email at [email protected]


MarketBeat Community Rating for Vermillion (VRML)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  139
MarketBeat's community ratings are surveys of what our community members think about Vermillion and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vermillion (NASDAQ:VRML) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.25$2.25$1.75$2.00
Price Target Upside: 53.12% upside53.12% upside32.58% upside52.67% upside

Vermillion (NASDAQ:VRML) Consensus Price Target History

Price Target History for Vermillion (NASDAQ:VRML)

Vermillion (NASDAQ:VRML) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/2/2017Canaccord GenuityBoost Price TargetBuy$1.75 -> $2.25N/AView Rating Details
(Data available from 12/11/2015 forward)

Earnings

Vermillion (NASDAQ:VRML) Earnings History and Estimates Chart

Earnings by Quarter for Vermillion (NASDAQ:VRML)

Vermillion (NASDAQ VRML) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.04)($0.06)$0.70 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.04)($0.04)$0.90 millionViewListenView Earnings Details
5/18/2017Q1 2017($0.04)($0.05)$0.73 millionViewN/AView Earnings Details
11/10/2016Q316($0.06)($0.07)$0.62 millionViewN/AView Earnings Details
8/10/2016Q216($0.09)($0.07)$0.71 millionViewListenView Earnings Details
5/16/2016Q116($0.09)($0.09)$0.51 millionViewListenView Earnings Details
3/24/2016Q415($0.10)$1.20 million$0.36 millionViewListenView Earnings Details
11/12/2015Q315($0.10)($0.10)$0.57 million$0.33 millionViewListenView Earnings Details
8/13/2015Q215($0.08)($0.11)$1.50 million$535.00 millionViewListenView Earnings Details
5/11/2015Q115($0.10)($0.10)$0.81 million$0.95 millionViewListenView Earnings Details
3/25/2015Q414($0.08)($0.11)$1.59 million$1.57 millionViewListenView Earnings Details
11/14/2013Q3($0.10)$319.00 million$330.00 millionViewListenView Earnings Details
8/14/2013Q2 2013($0.11)$0.32 million$0.23 millionViewListenView Earnings Details
5/15/2013Q1 2013($0.15)($0.17)$0.30 million$0.33 millionViewListenView Earnings Details
11/12/2012Q312($0.21)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Vermillion (NASDAQ:VRML) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Vermillion (NASDAQ:VRML)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Vermillion (NASDAQ VRML) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.67%
Institutional Ownership Percentage: 34.94%
Insider Trades by Quarter for Vermillion (NASDAQ:VRML)
Insider Trades by Quarter for Vermillion (NASDAQ:VRML)

Vermillion (NASDAQ VRML) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/15/2017Valerie Barber PalmieriCEOBuy685$1.46$1,000.10View SEC Filing  
10/16/2017Valerie Barber PalmieriInsiderBuy694$1.44$999.36View SEC Filing  
9/15/2017Valerie Barber PalmieriInsiderBuy719$1.39$999.41View SEC Filing  
8/23/2017Valerie Barber PalmieriInsiderBuy768$1.30$998.40View SEC Filing  
5/17/2017Valerie Barber PalmieriInsiderBuy555$1.80$999.00View SEC Filing  
2/17/2017Larry N FeinbergInsiderBuy617,731$1.40$864,823.40View SEC Filing  
2/13/2017Eric SchoenSVPBuy3,347$1.40$4,685.80View SEC Filing  
2/13/2017Jack W SchulerMajor ShareholderBuy974,081$1.40$1,363,713.40View SEC Filing  
2/13/2017Valerie Barber PalmieriCEOBuy10,042$1.40$14,058.80View SEC Filing  
2/13/2017Veronica Gh JordanDirectorBuy6,695$1.40$9,373.00View SEC Filing  
1/28/2016Jack W SchulerMajor ShareholderBuy1,493$1.60$2,388.80View SEC Filing  
1/25/2016Jack W SchulerMajor ShareholderBuy3,700$1.57$5,809.00View SEC Filing  
1/21/2016Jack W SchulerMajor ShareholderBuy30,700$1.46$44,822.00View SEC Filing  
1/19/2016Jack W SchulerMajor ShareholderBuy57,749$1.45$83,736.05View SEC Filing  
1/15/2016Jack W SchulerMajor ShareholderBuy8,400$1.56$13,104.00View SEC Filing  
7/14/2015Larry N FeinbergInsiderBuy512,043$1.96$1,003,604.28View SEC Filing  
12/23/2014Jack W SchulerMajor ShareholderBuy1,288,339$1.44$1,855,208.16View SEC Filing  
12/23/2014Larry N FeinbergInsiderBuy972,222$1.44$1,399,999.68View SEC Filing  
12/19/2014Peter S RoddyDirectorBuy16,502$1.44$23,762.88View SEC Filing  
11/21/2014Valerie Barber PalmieriCOOBuy3,500$1.51$5,285.00View SEC Filing  
11/20/2014James T LafranceInsiderBuy27,907$1.44$40,186.08View SEC Filing  
11/20/2014Valerie Barber PalmieriCOOBuy30,000$1.44$43,200.00View SEC Filing  
11/19/2014James T LafranceInsiderBuy41,615$1.43$59,509.45View SEC Filing  
11/18/2014Eric SchoenCAOBuy5,000$1.42$7,100.00View SEC Filing  
11/20/2013William B CreechVPBuy2,000$2.33$4,660.00View SEC Filing  
6/11/2013William B CreechVPBuy10,000$3.18$31,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vermillion (NASDAQ VRML) News Headlines

Source:
DateHeadline
Reviewing Vermillion (VRML) and InVitae (NVTA)Reviewing Vermillion (VRML) and InVitae (NVTA)
www.americanbankingnews.com - December 8 at 9:08 PM
Critical Survey: Vermillion (VRML) and Digiliti Money Group (DGLT)Critical Survey: Vermillion (VRML) and Digiliti Money Group (DGLT)
www.americanbankingnews.com - December 6 at 7:46 PM
Vermillion, Inc. (VRML) Downgraded by ValuEngine to SellVermillion, Inc. (VRML) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - November 25 at 6:46 AM
Vermillion to Present at the 29th Annual Piper Jaffray Healthcare ConferenceVermillion to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 22 at 5:28 PM
ASPiRA Labs Announces Release of Final CMS Reimbursement Rate for OVA1ASPiRA Labs Announces Release of Final CMS Reimbursement Rate for OVA1
finance.yahoo.com - November 20 at 12:07 PM
Vermillion Announces Publication of Foundational Health Economics StudyVermillion Announces Publication of Foundational Health Economics Study
finance.yahoo.com - November 18 at 10:08 AM
Vermillion, Inc. (VRML) Issues  Earnings Results, Misses Estimates By $0.02 EPSVermillion, Inc. (VRML) Issues Earnings Results, Misses Estimates By $0.02 EPS
www.americanbankingnews.com - November 9 at 2:52 PM
Vermillion Reports Third Quarter 2017 ResultsVermillion Reports Third Quarter 2017 Results
www.bizjournals.com - November 9 at 9:38 AM
Edited Transcript of VRML earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of VRML earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 9:38 AM
Vermillion to Present at the Canaccord Genuity 2017 Medical Technologies & Diagnostics ForumVermillion to Present at the Canaccord Genuity 2017 Medical Technologies & Diagnostics Forum
finance.yahoo.com - November 7 at 1:11 PM
Vermillion, Inc. (VRML) Price Target Raised to $2.25 at Canaccord GenuityVermillion, Inc. (VRML) Price Target Raised to $2.25 at Canaccord Genuity
www.americanbankingnews.com - November 2 at 7:42 PM
ASPiRA Labs Announces a Major Coverage Milestone - A 27% Increase in Covered Lives for OVA1ASPiRA Labs Announces a Major Coverage Milestone - A 27% Increase in Covered Lives for OVA1
finance.yahoo.com - November 1 at 10:32 AM
ASPiRA Labs Announces OVA1 Contract with Louisiana Blue Cross Blue ShieldASPiRA Labs Announces OVA1 Contract with Louisiana Blue Cross Blue Shield
finance.yahoo.com - October 31 at 11:57 AM
Vermillion to Report Third Quarter 2017 Financial Results and Host Investor Conference Call on November 8thVermillion to Report Third Quarter 2017 Financial Results and Host Investor Conference Call on November 8th
finance.yahoo.com - October 28 at 8:23 AM
ASPiRA Labs Lands Strategic Managed Care Coverage and Medicaid Licensure for OVA1®ASPiRA Labs Lands Strategic Managed Care Coverage and Medicaid Licensure for OVA1®
finance.yahoo.com - October 28 at 8:23 AM
ETFs with exposure to Vermillion, Inc. : October 2, 2017ETFs with exposure to Vermillion, Inc. : October 2, 2017
finance.yahoo.com - October 3 at 2:40 PM
ASPiRA Labs Announces In-Network Contract Agreement with HealthNet Federal Services for OVA1®ASPiRA Labs Announces In-Network Contract Agreement with HealthNet Federal Services for OVA1®
finance.yahoo.com - October 3 at 2:40 PM
Vermillion, Inc. (VRML) Sees Significant Increase in Short InterestVermillion, Inc. (VRML) Sees Significant Increase in Short Interest
www.americanbankingnews.com - September 30 at 3:50 AM
Is It Too Late To Buy Vermillion Inc (VRML)?Is It Too Late To Buy Vermillion Inc (VRML)?
finance.yahoo.com - September 23 at 10:49 AM
ETFs with exposure to Vermillion, Inc. : September 19, 2017ETFs with exposure to Vermillion, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 8:30 PM
Vermillion, Inc. :VRML-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017Vermillion, Inc. :VRML-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017
finance.yahoo.com - September 19 at 9:22 AM
Vermillion and ASPiRA Labs Kick Off Ovarian Cancer Awareness Month with 100,000th Patient Test Milestone and Ringing the Nasdaq Opening BellVermillion and ASPiRA Labs Kick Off Ovarian Cancer Awareness Month with 100,000th Patient Test Milestone and Ringing the Nasdaq Opening Bell
finance.yahoo.com - September 1 at 10:56 AM
Vermillion, Inc. (VRML) Receives "Buy" Rating from Canaccord GenuityVermillion, Inc. (VRML) Receives "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - August 30 at 4:56 PM
Critical Analysis: Vermillion (VRML) & CareDx (CDNA)Critical Analysis: Vermillion (VRML) & CareDx (CDNA)
www.americanbankingnews.com - August 25 at 2:12 PM
CareDx (CDNA) vs. Vermillion (VRML) Critical ComparisonCareDx (CDNA) vs. Vermillion (VRML) Critical Comparison
www.americanbankingnews.com - August 18 at 10:46 AM
Edited Transcript of VRML earnings conference call or presentation 9-Aug-17 8:30pm GMTEdited Transcript of VRML earnings conference call or presentation 9-Aug-17 8:30pm GMT
finance.yahoo.com - August 13 at 7:34 AM
Vermillion, Inc. (VRML) Releases Quarterly  Earnings Results, Hits EstimatesVermillion, Inc. (VRML) Releases Quarterly Earnings Results, Hits Estimates
www.americanbankingnews.com - August 10 at 6:21 PM
Vermillion Reports Second Quarter 2017 ResultsVermillion Reports Second Quarter 2017 Results
finance.yahoo.com - August 10 at 9:32 AM
Vermillion Announces Date Change of Second Quarter 2017 Financial Results and Investor Conference CallVermillion Announces Date Change of Second Quarter 2017 Financial Results and Investor Conference Call
finance.yahoo.com - August 5 at 8:22 AM
Vermillion to Present at the Canaccord Genuity 37th Annual Growth Conference on August 10thVermillion to Present at the Canaccord Genuity 37th Annual Growth Conference on August 10th
finance.yahoo.com - August 2 at 8:35 AM
Financial Survey: Veracyte (VCYT) and Vermillion (NASDAQ:VRML)Financial Survey: Veracyte (VCYT) and Vermillion (NASDAQ:VRML)
www.americanbankingnews.com - August 1 at 8:46 AM
Analyzing Veracyte (VCYT) & Vermillion (VRML)Analyzing Veracyte (VCYT) & Vermillion (VRML)
www.americanbankingnews.com - July 31 at 2:23 PM
Vermillion to Report Second Quarter 2017 Financial Results and Host Investor Conference Call on August 8thVermillion to Report Second Quarter 2017 Financial Results and Host Investor Conference Call on August 8th
finance.yahoo.com - July 28 at 9:47 AM
Vermillion (NASDAQ:VRML) vs. InVitae Corp (NVTA) Head-To-Head SurveyVermillion (NASDAQ:VRML) vs. InVitae Corp (NVTA) Head-To-Head Survey
www.americanbankingnews.com - July 24 at 2:14 PM
Vermillion (VRML) vs. Lion Biotechnologies (IOVA) Head-To-Head ComparisonVermillion (VRML) vs. Lion Biotechnologies (IOVA) Head-To-Head Comparison
www.americanbankingnews.com - July 20 at 6:27 PM
 Vermillion, Inc. (NASDAQ:VRML) Receives Average Recommendation of "" from Analysts Vermillion, Inc. (NASDAQ:VRML) Receives Average Recommendation of "" from Analysts
www.americanbankingnews.com - July 17 at 8:14 PM
Critical Survey: Vermillion (VRML) vs. InVitae Corp (NVTA)Critical Survey: Vermillion (VRML) vs. InVitae Corp (NVTA)
www.americanbankingnews.com - July 14 at 12:08 AM
ETFs with exposure to Vermillion, Inc. : July 11, 2017ETFs with exposure to Vermillion, Inc. : July 11, 2017
finance.yahoo.com - July 12 at 9:05 AM
Affymetrix (AFFX) versus Vermillion (VRML) Critical ContrastAffymetrix (AFFX) versus Vermillion (VRML) Critical Contrast
www.americanbankingnews.com - July 1 at 10:04 PM
After raising $2 million, Austins Consortia Health tackles problems that might make some blushAfter raising $2 million, Austin's Consortia Health tackles problems that might make some blush
www.bizjournals.com - April 15 at 7:00 PM
VERMILLION, INC. Files SEC form 10-K, Annual ReportVERMILLION, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - April 1 at 9:38 AM
Q4 2016 Vermillion Inc Earnings Release - Before Market OpenQ4 2016 Vermillion Inc Earnings Release - Before Market Open
biz.yahoo.com - March 29 at 10:17 AM
VERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsVERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - March 13 at 8:09 PM
VERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal OfficersVERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 4 at 3:56 AM
ASPiRA LABs Announces Contracted In-Network Agreement with Blue Cross Blue Shield of Michigan for OVA1®ASPiRA LABs Announces Contracted In-Network Agreement with Blue Cross Blue Shield of Michigan for OVA1®
www.bizjournals.com - March 2 at 1:23 AM
VERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SecuritiVERMILLION, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securiti
biz.yahoo.com - February 17 at 5:05 PM
Vermillion Announces Equity Financing of $5.6 MillionVermillion Announces Equity Financing of $5.6 Million
us.rd.yahoo.com - February 14 at 3:49 PM
VERMILLION, INC. Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and ExhibitsVERMILLION, INC. Files SEC form 8-K/A, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 9 at 3:53 PM
VERMILLION, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsVERMILLION, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 7 at 6:22 AM
4:06 pm Vermillion & ASPiRA LABS announce receipt of formal FDA clarification regarding ovarian cancer screening alert4:06 pm Vermillion & ASPiRA LABS announce receipt of formal FDA clarification regarding ovarian cancer screening alert
us.rd.yahoo.com - January 6 at 6:31 AM

SEC Filings

Vermillion (NASDAQ:VRML) SEC Filings

DateFilerForm TypeView

Social Media

Financials

Vermillion (NASDAQ:VRML) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vermillion (NASDAQ VRML) Stock Chart for Monday, December, 11, 2017

Loading chart…

This page was last updated on 12/11/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.